JP2017516862A - アンドロゲン受容体調節物質及びその使用方法 - Google Patents

アンドロゲン受容体調節物質及びその使用方法 Download PDF

Info

Publication number
JP2017516862A
JP2017516862A JP2017515034A JP2017515034A JP2017516862A JP 2017516862 A JP2017516862 A JP 2017516862A JP 2017515034 A JP2017515034 A JP 2017515034A JP 2017515034 A JP2017515034 A JP 2017515034A JP 2017516862 A JP2017516862 A JP 2017516862A
Authority
JP
Japan
Prior art keywords
cancer
compound
haloalkyl
prostate cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516862A5 (enExample
Inventor
ルピン ヤン，
ルピン ヤン，
レイモンド ジェイ． アンデルセン，
レイモンド ジェイ． アンデルセン，
マリアンヌ ドロシー サダル，
マリアンヌ ドロシー サダル，
ナスリン アール． マウジ，
ナスリン アール． マウジ，
カルメン アドリアナ バヌエロス，
カルメン アドリアナ バヌエロス，
Original Assignee
ブリティッシュ コロンビア キャンサー エージェンシー ブランチ
ブリティッシュ コロンビア キャンサー エージェンシー ブランチ
ザ ユニヴァーシティ オブ ブリティッシュ コロンビア
ザ ユニヴァーシティ オブ ブリティッシュ コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリティッシュ コロンビア キャンサー エージェンシー ブランチ, ブリティッシュ コロンビア キャンサー エージェンシー ブランチ, ザ ユニヴァーシティ オブ ブリティッシュ コロンビア, ザ ユニヴァーシティ オブ ブリティッシュ コロンビア filed Critical ブリティッシュ コロンビア キャンサー エージェンシー ブランチ
Publication of JP2017516862A publication Critical patent/JP2017516862A/ja
Publication of JP2017516862A5 publication Critical patent/JP2017516862A5/ja
Priority to JP2020089519A priority Critical patent/JP6925481B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017515034A 2014-05-30 2015-05-29 アンドロゲン受容体調節物質及びその使用方法 Pending JP2017516862A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020089519A JP6925481B2 (ja) 2014-05-30 2020-05-22 アンドロゲン受容体調節物質及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462005714P 2014-05-30 2014-05-30
US62/005,714 2014-05-30
PCT/US2015/033385 WO2015184393A1 (en) 2014-05-30 2015-05-29 Androgen receptor modulators and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020089519A Division JP6925481B2 (ja) 2014-05-30 2020-05-22 アンドロゲン受容体調節物質及びその使用方法

Publications (2)

Publication Number Publication Date
JP2017516862A true JP2017516862A (ja) 2017-06-22
JP2017516862A5 JP2017516862A5 (enExample) 2018-07-05

Family

ID=53373659

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515034A Pending JP2017516862A (ja) 2014-05-30 2015-05-29 アンドロゲン受容体調節物質及びその使用方法
JP2020089519A Active JP6925481B2 (ja) 2014-05-30 2020-05-22 アンドロゲン受容体調節物質及びその使用方法
JP2021127354A Pending JP2021176908A (ja) 2014-05-30 2021-08-03 アンドロゲン受容体調節物質及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020089519A Active JP6925481B2 (ja) 2014-05-30 2020-05-22 アンドロゲン受容体調節物質及びその使用方法
JP2021127354A Pending JP2021176908A (ja) 2014-05-30 2021-08-03 アンドロゲン受容体調節物質及びその使用方法

Country Status (8)

Country Link
US (2) US9682933B2 (enExample)
EP (1) EP3148970B1 (enExample)
JP (3) JP2017516862A (enExample)
AU (3) AU2015266654A1 (enExample)
CA (1) CA2948643C (enExample)
IL (1) IL249203B (enExample)
NZ (1) NZ726348A (enExample)
WO (1) WO2015184393A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021517119A (ja) * 2018-03-05 2021-07-15 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置
JP2022547885A (ja) * 2019-09-05 2022-11-16 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスと、ｃｄｋ４／６阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009284668B2 (en) * 2008-08-22 2015-07-09 British Columbia Cancer Agency Branch Small molecule inhibitors of N-terminus activation of the androgen receptor
WO2015184393A1 (en) 2014-05-30 2015-12-03 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2021021629A1 (en) * 2019-07-26 2021-02-04 University Of Florida Research Foundation, Incorporated Discovery, total synthesis, and bioactivity of doscadenamides
US12133846B2 (en) 2019-10-15 2024-11-05 Wayne State University Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500778A (ja) * 2008-08-22 2012-01-12 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体のｎ末端の活性化の小分子阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0317057A (ja) 1989-06-15 1991-01-25 Fujisawa Pharmaceut Co Ltd 新規５員環複素環化合物
CA2302169A1 (en) 1998-06-30 2000-01-13 The University Of British Columbia Inhibitors of androgen-independent activation of androgen receptor
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
WO2012047617A1 (en) * 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
WO2015184393A1 (en) 2014-05-30 2015-12-03 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500778A (ja) * 2008-08-22 2012-01-12 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体のｎ末端の活性化の小分子阻害剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021517119A (ja) * 2018-03-05 2021-07-15 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置
JP2022547885A (ja) * 2019-09-05 2022-11-16 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスと、ｃｄｋ４／６阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置

Also Published As

Publication number Publication date
IL249203A0 (en) 2017-01-31
WO2015184393A1 (en) 2015-12-03
NZ726348A (en) 2022-09-30
US9682933B2 (en) 2017-06-20
IL249203B (en) 2020-08-31
JP2021176908A (ja) 2021-11-11
EP3148970A1 (en) 2017-04-05
US20170283377A1 (en) 2017-10-05
CA2948643A1 (en) 2015-12-03
EP3148970B1 (en) 2022-03-16
US20150344424A1 (en) 2015-12-03
AU2015266654A1 (en) 2016-12-01
AU2019257509A1 (en) 2019-11-21
AU2019257509B2 (en) 2021-05-13
CA2948643C (en) 2022-09-06
US10071962B2 (en) 2018-09-11
JP6925481B2 (ja) 2021-08-25
AU2021215137A1 (en) 2021-09-02
JP2020143126A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
JP6925481B2 (ja) アンドロゲン受容体調節物質及びその使用方法
AU2014262333B2 (en) Ester derivatives of androgen receptor modulators and methods for their use
US9365510B2 (en) Aziridine bisphenol ethers and related compounds and methods for their use
US11779550B2 (en) Bisphenol ether derivatives and methods for using the same
JP6884100B2 (ja) がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法
JP2016530285A (ja) 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法
CN105012282A (zh) 二缩水甘油醚衍生物治疗剂和它们的使用方法
WO2012145330A1 (en) Fluorene-9-bisphenol compounds and methods for their use
WO2012145328A1 (en) Dibenzylphenyl compounds and methods for their use
WO2016058080A1 (en) Fluoro-chloro bisphenol ether compounds and methods for their use
OA18988A (en) Ester derivatives of androgen receptor modulators and methods for their use.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200124